воскресенье, 28 февраля 2016 г.

Noble Financial Reaffirms "Buy" Rating for BioCryst Pharmaceuticals, Inc.

Noble Financial Reaffirms "Buy" Rating for BioCryst Pharmaceuticals, Inc.


's stock had its "buy" rating restated by Noble Financial in a research report issued to clients and investors on Friday, Analyst Ratings Network.com reports. They presently have a $8.00 target price on the biotechnology company's stock.



from Biotech News